Biointron, an antibody contract research organization, launched a new developability platform that helps drug developers identify manufacturing problems early, potentially saving millions by catching ...
EPS beat, 3–6% core growth outlook, bioprocess strength, Masimo synergies, China/respiratory headwinds—read now.
Q1 2026 Earnings Call April 21, 2026 8:00 AM EDTCompany ParticipantsRachel VatnsdalRainer Blair - President, CEO ...
An innovative gene-editing strategy could establish a new way for the body to manufacture therapeutic proteins—including ...
Zasocitinib, which is a potent and highly selective TYK2 inhibitor would be a good option for some of our patients who are ...
(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) By ...
Researchers used CRISPR to edit hematopoietic stem cells, creating B cells that produce neutralizing antibodies against HIV, ...
Day Candidate Antibody Discovery - Sanyou AI-STAL 2.0 Defines the Era of Ultimate Speed in Drug Molecule Discovery ...
Your early life may quietly set the stage for developing Type 1 diabetes, an increasingly common, lifelong condition that can ...
Discover some of the new atopic dermatitis treatments in clinical development that could overcome existing challenges in the ...
Astellas manufacturing chief views reliable supply, bridging research as his production 'north star'
For Astellas’ chief manufacturing officer Rao Mantri, Ph.D.—who entered the position a little over a year ago—production is ...
Oxford, UK – 16th April 2026 - Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results